Comparison
Alpha-Lipoic Acid vs Tirzepatide
Side-by-side of Alpha-Lipoic Acid and Tirzepatide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Alpha-Lipoic Acid
Alpha lipoic acid supplement guide: 600 mg/day oral dosing, R-ALA vs racemic absorption, neuropathy trial data, antioxidant mechanism, interactions.
Tirzepatide
Tirzepatide for weight loss: dual GIP/GLP-1 agonist sold as Mounjaro and Zepbound. SURMOUNT-1 showed 22.5% mean body-weight loss at 15 mg over 72 weeks.
Effects at a glance
Alpha-Lipoic Acid
- •Approved Rx for diabetic neuropathy in Germany at 600 mg/day IV (Thioctacid) since 1960s
- •Improves neuropathy symptoms (TSS, NIS) at 600 mg/day IV across ALADIN and SYDNEY trials
- •R-ALA enantiomer absorbs 40-100% better than racemic mixtures
- •Activates AMPK; produces small HbA1c reductions in T2DM
- •Plasma half-life ~30 minutes; split dosing or sustained-release is standard
- •Hypoglycemia risk with insulin or sulfonylureas; medication adjustment may be required
Tirzepatide
- •Dual GIP plus GLP-1 receptor agonist with a ~5-day half-life supporting once-weekly subcutaneous dosing
- •SURMOUNT-1 reported ~22.5% mean body-weight loss at 15 mg over 72 weeks versus 2.4% on placebo
- •Lowers HbA1c by ~1.9 to 2.6 percentage points in type 2 diabetes across SURPASS trials
- •Outperformed semaglutide 1.0 mg head-to-head on weight loss and HbA1c in SURPASS-2
- •GI effects (nausea, diarrhea, vomiting) drive most discontinuations and ease with slow titration
- •Lean-mass loss observed in body-composition substudies; resistance training and protein intake mitigate this
Side-by-side
| Attribute | Alpha-Lipoic Acid | Tirzepatide |
|---|---|---|
| Category | supplement | pharmaceutical |
| Also known as | ALA, thioctic acid, R-ALA, R-lipoic acid | Mounjaro, Zepbound, LY3298176 |
| Half-life (hr) ↗ | 0.5 | 120 |
| Typical dose (mg) ↗ | 600 | 10 |
| Dosing frequency | 1 to 3 times daily on empty stomach | weekly |
| Routes | oral, iv | subcutaneous |
| Onset (hr) | 0.5 | 24 |
| Peak (hr) | 1 | 72 |
| Molecular weight | 206.33 | 4813.45 |
| Molecular formula | C8H14O2S2 | C225H348N48O68 |
| Mechanism | Dual lipid- and water-soluble antioxidant; redox cycles with dihydrolipoic acid (DHLA) to scavenge ROS, regenerate vitamin E and C, and chelate transition metals. Activates AMPK in liver and muscle; cofactor for pyruvate and alpha-ketoglutarate dehydrogenase complexes. | Synthetic 39-amino-acid peptide that activates both GIP and GLP-1 receptors. Potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic and brainstem satiety circuits. |
| Legal status | Dietary supplement (US, UK, Canada, most EU); prescription drug for diabetic neuropathy in Germany | Prescription only; FDA-approved 2022 (T2DM, Mounjaro) and 2023 (chronic weight management, Zepbound) |
| WADA status | allowed | allowed |
| DEA / Rx | Not scheduled | Rx only (not a controlled substance) |
| Pregnancy | Insufficient data; precautionary avoidance | Not recommended; discontinue 2 months before planned pregnancy |
| CAS | 62-46-4 | 2023788-19-2 |
| PubChem CID | 864 | 156588324 |
| Wikidata | Q161227 | Q105099794 |
Safety profile
Alpha-Lipoic Acid
Common side effects
- nausea
- abdominal discomfort
- diarrhea
- sulfurous odor
- rash (rare)
Contraindications
- pregnancy and lactation (insufficient safety data)
- active insulin autoimmune syndrome predisposition
Interactions
- insulin and sulfonylureas: additive hypoglycemia; medication dose adjustment may be required(major)
- thyroid hormone: may reduce T4 to T3 conversion at high doses(moderate)
- biotin: ALA competes with biotin uptake; chronic use can induce biotin insufficiency(minor)
- iron supplements: ALA chelates iron and reduces absorption; separate dosing(moderate)
- chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)
Tirzepatide
Common side effects
- nausea
- diarrhea
- vomiting
- constipation
- decreased appetite
- injection-site reactions
- fatigue
- abdominal pain
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
- severe gastroparesis
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- oral contraceptives: reduced exposure after first dose; backup contraception recommended for 4 weeks after initiation and each dose escalation(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
Which Should You Take?
Alpha-Lipoic Acid comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Tirzepatide is the right call when one of the conditionals below applies.
- → If your priority is healthspan extension, pick Alpha-Lipoic Acid.
- → If your priority is long-term neuroprotection, pick Alpha-Lipoic Acid.
- → If your priority is fat loss, pick Tirzepatide.
- → If your priority is glycemic control, pick Tirzepatide.
Edge case: If you want to avoid prescription-only, Alpha-Lipoic Acid is the more accessible choice.
Default choice: Alpha-Lipoic Acid. Lower friction to source, and broader goal coverage. Reach for Tirzepatide only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Alpha-Lipoic Acid and Tirzepatide?
Alpha-Lipoic Acid and Tirzepatide differ in category (supplement vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Alpha-Lipoic Acid or Tirzepatide?
Alpha-Lipoic Acid half-life is 0.5 hours; Tirzepatide half-life is 120 hours.
Can you stack Alpha-Lipoic Acid with Tirzepatide?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper